A 4-year-old neutered-male Australian Shepherd was presented to an emergency and referral hospital for an acute onset of neurologic signs and abnormal mentation. Seven days prior, the patient had been diagnosed with hypoadrenocorticism and was treated accordingly at another hospital. Based on recent clinical history, the neurologic signs were consistent with thalamic and brainstem deficits and suspected to be caused by osmotic demyelination syndrome secondary to rapid correction of hyponatremia. A brain MRI confirmed lesions consistent with osmotic demyelination syndrome. The patient's clinical signs initially worsened, and he required intensive nursing care with multimodal sedation, close monitoring of electrolytes and tailored fluid therapy. The patient recovered and was discharged on day seven of hospitalization. Four and a half months later, re-evaluation of the patient showed complete resolution of the neurological deficits with a now unremarkable neurological exam, and follow-up MRI revealed still present, yet improved bilateral thalamic lesions. This is the first known veterinary case report of sequential brain imaging of a dog that has recovered from osmotic demyelination syndrome. In humans, patients can have evidence of near to full clinical recovery, yet imaging findings may still be abnormal several months after recovery. This report details similar imaging findings in a canine with improved clinical signs, despite persistent lesions on brain MRI. Prognosis of canines with osmotic demyelination syndrome may be better than previously perceived, despite the severity of clinical signs and brain lesions apparent on MRI.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175592PMC
http://dx.doi.org/10.3389/fvets.2023.1146091DOI Listing

Publication Analysis

Top Keywords

osmotic demyelination
20
demyelination syndrome
20
clinical signs
12
case report
8
neurologic signs
8
brain mri
8
imaging findings
8
osmotic
5
demyelination
5
syndrome
5

Similar Publications

Objectives: The recommended dose of tolvaptan for hyponatraemia secondary to SIADH is 15mg. We evaluated the efficacy of an initial 7.5mg dose and determined the frequency where sodium (Na+) correction exceeded safe limits, defined as an increment of ≥10 mmol/L, within the initial 8 or 24 hours of administration.

View Article and Find Full Text PDF

Osmotic demyelination syndrome: Case report and literature retrospect.

Medicine (Baltimore)

December 2024

Department of Neurology and Department of Neuroscience, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.

Rationale: Osmotic demyelination syndrome (ODS) is a noninflammatory demyelinating disorder involving the pontis and other regions of the central nervous system. This article tries to enhance the understanding of ODS. Combined with clinical features, we use laboratory/imaging examination and literature review.

View Article and Find Full Text PDF
Article Synopsis
  • This study investigates adverse events associated with topiramate using data from the FDA Adverse Event Reporting System, aiming to improve its safe clinical use.
  • The analysis reviewed 12,168 reports and identified 244 positive signals of adverse reactions, with 21 of these being serious and not listed on the drug label.
  • Key serious signals included conditions like hypospadias, spina bifida, and renal dysfunction, highlighting the necessity for ongoing vigilance in monitoring topiramate's safety.
View Article and Find Full Text PDF

A pregnant woman was brought to the emergency department looking starved and neglected. She was diagnosed with sepsis and started on intravenous antibiotics. She was also disoriented and hypernatremic.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!